Health TrialsbyHealthPanel

Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease

ConditionPARKINSON DISEASE (Disorder)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorPusan National University Yangsan Hospital

About this trial

This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination

Adults aged 40 years or older

Individuals able to walk independently

Disqualifiers

Individuals with severe cognitive impairment (Korean Mini-Mental State Examination [K-MMSE] score ≤ 9) making it difficult to understand and perform tasks

Patients with dementia other than Parkinson's disease dementia

Individuals with implanted medical or other electronic devices

Individuals with severe neuropsychiatric disorders

Trial design

Design model

Single group

Treatments tested in this trial

  • Photobiomodulation

    Device

    Participants received whole-body PBM therapy over approximately 10 weeks (three sessions per week, once daily, 20 minutes per session), with each session using a randomly selected wavelength of either 660 nm, 850 nm, or 940 nm (±20%).

Treatment groups

15 Participants
are divided into 1 treatment group
Group A: ParkinsonExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

UPDRS

Unified Parkinson's Disease Rating Scale

Time frame
Change in UPDRS from baseline to post 30 sessions (up to approximately 10 weeks). The UPDRS ranges from 0 to 199, with higher scores indicating greater symptom severity.

Secondary outcomes

1

BBS

Berg Balance Scale

Time frame
Change in Berg Balance Scale scores from baseline to post 30 sessions (up to approximately 10 weeks). The BBS ranges from 0 to 56, with higher scores indicating better balance performance.
2

Grip strength and pinch strength test

Grasp, tip pinch \& three jaw chuck

Time frame
Change in Grip strength and pinch strength from baseline to post 30 sessions (up to approximately 10 weeks). Higher scores indicate better hand function.
3

FRT

Functional Reach Test

Time frame
Change in Functional Reach Test scores from baseline to post 30 sessions (up to approximately 10 weeks). Higher scores indicate better hand function.
4

TUG

Timed Up and Go

Time frame
Change in Timed Up and Go test scores from baseline to post 30 sessions (up to approximately 10 weeks). Lower scores indicate better functional mobility.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Pusan National University Yangsan Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now